comparemela.com

Latest Breaking News On - Curasight - Page 1 : comparemela.com

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

/PRNewswire/ Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic.

Ulrich krasilnikoffCurium incCurasight pressComing phasePress release

Curasight A/S Achieves First Milestone under collaboration with Curium Inc

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in.

United statesUlrich krasilnikoffCurium incDrug administrationCurium first

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

/PRNewswire/ Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the.

Czech republicAleena azamUlrich krasilnikoffWorld molecular imaging congressUniversity of copenhagenPrimary gliomasPrognostic valueTargeted radionuclideMolecular imagingSpringer publisherPositron emissions tomographyRadionuclide therapy

Curasight A/S reports positive preclinical results with uTREAT® in aggressive brain cancer (glioblastoma)

/PRNewswire/ Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT®.

Ulrich krasilnikoff

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023

Ulrich krasilnikoffCurasightas curasightAndreas kjLife science investor conferencePositron emissions tomographyCurasightas stock exchangePress releaseT curas dk0061295797

vimarsana © 2020. All Rights Reserved.